• Trent C Martin, Brittney E Duewell, Janelle J Juul, Joseph R G Rinka, Lisa Rein, and Joel T Feih.
• Department of Pharmacy, Froedtert Hospital, Milwaukee, WI. Electronic address: trentmartin@virginia.edu.
• J. Cardiothorac. Vasc. Anesth. 2024 Jun 1; 38 (6): 132813361328-1336.

ObjectivesTo evaluate the safety of cangrelor administered concurrently with heparin or bivalirudin in patients on mechanical circulatory support.DesignA single-center, retrospective cohort study of adult patients consecutively admitted between January 2016 and October 2020.SettingA tertiary medical center.ParticipantsAdult patients admitted to the cardiovascular intensive care unit put on mechanical circulatory support for acute myocardial infarction (AMI) or non-AMI indications. Patients who received cangrelor underwent percutaneous coronary intervention with stenting during the index event or within the last year.InterventionsNone.Measurements And Main ResultsThe primary outcome was the incidence of major bleeding, defined by the Extracorporeal Life Support Organization criteria, in patients with mechanical circulatory support receiving cangrelor plus anticoagulation with heparin or bivalirudin with or without aspirin versus patients who did not receive cangrelor. Sixty-eight patients were included in the study. Twenty-nine patients received cangrelor, and 39 did not. Cangrelor was not associated with an increase in major bleeding; however, the CI was wide (adjusted hazard ratio 1.93, 95% CI 0.61-6.11; p = 0.262).ConclusionsPatients receiving cangrelor did not appear to be at higher risk of major bleeding compared to patients not receiving cangrelor. Larger trials should be conducted to better evaluate the safety of cangrelor in patients with mechanical circulatory support.Copyright © 2024 Elsevier Inc. All rights reserved.

41 keywords...

hide…